Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study.
Crommentuyn
Kristel M
KM
Huitema
Alwin D
AD
Brinkman
Kees
K
van der Ende
Marchina E
ME
de Wolf
Frank
F
Beijnen
Jos H
JH
D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000097:blood / Q000493:pharmacokinetics*; D016903:Drug Monitoring / Q000379:methods*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D019829:Nevirapine